Analyst initiations: PCLN, GTXI, AKNS and NEXM

Posted Mar 25th 2008 11:57AM by Eric Buscemi
Filed under: Analyst Reports, Analyst Initiations

MOST NOTEWORTHY: GTX Inc, Akeena Solar and NexMed were today's noteworthy initiations:

Rodman & Renshaw is positive on GTX Inc's (NASDAQ: GTXI) opportunity for Acapodene in prostate cancer and Ostarine for muscle wasting. The firm started shares with an Outperform rating and $22 target.
Akeena Solar (NASDAQ: AKNS) was initiated with a Buy rating at Merriman. The firm believes the company is positioned to generate a high margin recurring revenue stream through the licensing of its Andalay proprietary rack mounting system.
Roth Capital expects NexMed's (NASDAQ: NEXM) Phase III data for its antifungal Lamisil, expected in mid-2008, to be positive. The firm, which started NexMed with a Buy rating and $2.50 target, said early clinical data demonstrated a roughly 7-8X improvement in fungal reductions versus the competitive topical formulation sold as Penlac. The analyst said Phase III trial will admittedly have a different end point, but this data makes them bullish.

OTHER INITIATIONS:

Lehman initiated Liberty Entertainment (NASDAQ: LMDIA) with an Overweight rating and $30 target.
Canaccord Adams assumed Priceline.com (NASDAQ: PCLN) with a Hold rating and $120 target.
Home Inns (NASDAQ: HMIN) was started at Morgan Stanley with an Overweight rating and $28 target.

Tags: akeena solar, AkeenaSolar, analyst, gtx, gtxi, hmin, home inns, HomeInns, initiation, liberty entertainment, LibertyEntertainment, lmdia, nexm, nexmed, pcln, priceline